1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET BY SERVICE TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 INDONESIA CLINICAL LABORATORY SERVICES MARKET CLINICAL LABORATORY SERVICES MARKET: REGULATIONS
5.1 REGULATIONS IN THAILAND
5.2 REGULATIONS IN PHILIPPINES
5.3 REGULATIONS IN MALAYSIA
5.4 REGULATION IN INDONESIA
6 REIMBURSEMENT SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES
7.1.2 ADVANCEMENTS IN CLINICAL DIAGNOSTIC METHODS
7.1.3 DEVELOPMENT IN DATABASE MANAGEMENT TOOLS AND WIDE ACCEPTANCE OF POINT-OF-CARE (POC) TESTING SOLUTIONS
7.1.4 RISING DEMAND FOR EARLY AND ACCURATE DISEASE DIAGNOSIS
7.1.5 RISING PER CAPITA INCOME
7.2 RESTRAINTS
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.2.2 STRICT REGULATORY POLICIES
7.3 OPPORTUNITIES
7.3.1 GROWING ADOPTION OF DIGITAL PATHOLOGY PLATFORMS
7.3.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.3.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE
7.3.4 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 INACCURATE RESULTS OF TESTS
7.4.2 INADEQUATE REIMBURSEMENTS POLICIES
8 IMPACT OF COVID-19
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 INDONESIA CLINICAL LABORATORY SERVICES MARKET, BY SERVICE TYPE
9.1 OVERVIEW
9.2 ROUTINE TESTING SERVICES
9.2.1 ROUTINE CHEMISTRY TESTING
9.2.2 ROUTINE HEMATOLOGY TESTING
9.2.3 URINALYSIS TESTING
9.2.4 SUBSTANCE ABUSE TESTING
9.2.5 OTHERS
9.3 ESOTERIC SERVICES
9.4 ANATOMIC PATHOLOGY SERVICES
9.4.1 CYTOLOGY TESTING
9.4.2 DIAGNOSTIC SURGICAL PATHOLOGY TESTING
9.4.3 AUTOPSY PATHOLOGY
9.4.4 OTHERS
10 INDONESIA CLINICAL LABORATORY SERVICES MARKET, BY SPECIALTY
10.1 OVERVIEW
10.2 CLINICAL CHEMISTRY TESTING
10.2.1 ROUTINE CHEMISTRY TESTING
10.2.2 THERAPEUTIC DRUG MONITORING (TDM) TESTING
10.2.3 SPECIALIZED CHEMISTRY TESTING
10.2.4 OTHER CLINICAL CHEMISTRY TESTING
10.3 HEMATOLOGY TESTING
10.3.1 ROUTINE HEMATOLOGY TESTING
10.3.2 SPECIALIZED HEMATOLOGY TESTING
10.3.3 COAGULATION TESTING
10.4 MICROBIOLOGY TESTING
10.4.1 INFECTIOUS DISEASE TESTING
10.4.2 TRANSPLANT DIAGNOSTIC TESTING
10.4.3 OTHER MICROBIOLOGY TESTING
10.5 IMMUNOLOGY TESTING
10.6 DRUGS OF ABUSE TESTING
10.7 CYTOLOGY TESTING
10.8 GENETIC TESTING
11 INDONESIA CLINICAL LABORATORY SERVICES MARKET, BY PROVIDER
11.1 OVERVIEW
11.2 HOSPITAL-BASED LABORATORIES
11.3 INDEPENDENT & REFERENCE LABORATORIES
11.4 NURSING AND PHYSICIAN OFFICE-BASED LABORATORIES
12 INDONESIA CLINICAL LABORATORY SERVICES MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 BIOANALYTICAL & LAB CHEMISTRY SERVICES
12.3 DRUG DEVELOPMENT RELATED SERVICES
12.4 DRUG DISCOVERY RELATED SERVICES
12.5 TOXICOLOGY TESTING SERVICES
12.6 CELL & GENE THERAPY RELATED SERVICES
12.7 PRECLINICAL & CLINICAL TRIAL RELATED SERVICES
12.8 OTHER CLINICAL LABORATORY SERVICES
13 INDONESIA CLINICAL LABORATORY SERVICES MARKET, BY COUNTRY
13.1 INDONESIA
14 THAILAND CLINICAL LABORATORY SERVICES MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: THAILAND
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 ANDALAB MEDICAL LABORATORIES
16.2.1 COMPANY SNAPSHOT
16.2.2 SERVICE PORTFOLIO
16.2.3 RECENT DEVELOPMENT
16.3 BRIANET
16.3.1 COMPANY SNAPSHOT
16.3.2 SERVICE PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 CHARLES RIVER LABORATORIES
16.4.1 COMPANY SNAPSHOT
16.4.2 RECENT FINANCIALS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 CITO CLINICAL LABORATORY
16.5.1 COMPANY SNAPSHOT
16.5.2 SERVICE PORTFOLIO
16.5.3 RECENT DEVELOPMENTS
16.6 DAVITA INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 RECENT FINANCIALS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 EUROFINS SCIENTIFIC
16.7.1 COMPANY SNAPSHOT
16.7.2 RECENT FINANCIALS
16.7.3 SERVICE PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 KERALTY
16.8.1 COMPANY SNAPSHOT
16.8.2 SERVICE PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 LABSERV INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 SERVICE PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 LABORATORY CORPORATION OF AMERICA® HOLDINGS
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 SERVICE PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 MAYON CLINICAL LABORATORIES
16.11.1 COMPANY SNAPSHOT
16.11.2 SERVICE PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 MEDI LINX LABORATORY, INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 SERVICE PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 QUEST DIAGNOSTICS INCORPORATED
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 SERVICE PORTFOLIO
16.13.4 RECENT DEVELOPMENTS
16.14 PARAHITA DIAGNOSTIC CENTER
16.14.1 COMPANY SNAPSHOT
16.14.2 SERVICE PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 PRODIA
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 SERVICE PORTFOLIO
16.15.4 RECENT DEVELOPMENT
16.16 PT KIMIA FARMA DIAGNOSTIKA
16.16.1 COMPANY SNAPSHOT
16.16.2 SERVICE PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 SGS SA
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 SERVICE PORTFOLIO
16.17.4 RECENT DEVELOPMENTS
16.18 SIEMENS HEALTHCARE GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 RECENT FINANCIALS
16.18.3 SERVICE PORTFOLIO
16.18.4 RECENT DEVELOPMENTS
16.19 SUNWAY MED LAB
16.19.1 COMPANY SNAPSHOT
16.19.2 SERVICE PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 SYNEOS HEALTH
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 SERVICE PORTFOLIO
16.20.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS